Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIAMINIC-12 vs VOSOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Chlorpheniramine is an antihistamine that competitively antagonizes histamine H1 receptors, preventing histamine-mediated symptoms such as sneezing, rhinorrhea, and pruritus.
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
Temporary relief of nasal congestion,Sinus congestion and pressure,Runny nose,Sneezing,Itchy nose or throat,Allergic rhinitis symptoms
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
Oral: 1 tablet (75 mg of pseudoephedrine hydrochloride and 4 mg of chlorpheniramine maleate) every 12 hours, not to exceed 2 tablets in 24 hours.
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
Chlorpheniramine: 12-15 hours (terminal) in adults, extended in hepatic impairment or elderly. Pseudoephedrine: 5-8 hours (terminal) in adults with normal renal function, prolonged in renal impairment (up to 20 hours). The combination product's duration is determined by chlorpheniramine.
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Pseudoephedrine is partially metabolized in the liver by N-demethylation to norpseudoephedrine, with about 70-90% excreted unchanged in urine. Chlorpheniramine is extensively metabolized in the liver via CYP2D6 and other pathways, including N-demethylation and oxidative deamination.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Triaminic-12 contains chlorpheniramine and pseudoephedrine. Chlorpheniramine: ~50% renal as metabolites, <1% unchanged. Pseudoephedrine: ~70-90% renal unchanged, remainder as metabolites. Total elimination: renal > 90%, fecal < 10%.
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
Chlorpheniramine: ~70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible binding (<10%).
90–95%, primarily to albumin.
Chlorpheniramine: 3-4 L/kg (widespread distribution, including CNS). Pseudoephedrine: 2-3 L/kg (distributes into body tissues).
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Chlorpheniramine oral: ~25-50% due to first-pass metabolism (extensive hepatic CYP450). Pseudoephedrine oral: ~75-100% well absorbed, minimal first-pass.
Otic: 80–90% (local absorption with minimal systemic).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min), reduce frequency to every 24 hours. No adjustment for mild impairment.
No dosage adjustment required for renal impairment.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, use with caution and consider reducing dose frequency to every 24 hours due to increased half-life.
No dosage adjustment required for hepatic impairment.
Not recommended for children under 12 years. For children 12 years and older, use adult dosing.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
For patients >65 years: use with caution due to increased risk of anticholinergic effects and potential for hypertension or tachycardia. Consider starting with 1 tablet every 24 hours and monitor response.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
None
None
Use with caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, or urinary retention. May cause dizziness or drowsiness; avoid alcohol and other CNS depressants. Do not exceed recommended dosage. Not for use in children under 12 years.
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Hypersensitivity to any component. Concomitant use with MAO inhibitors or within 2 weeks of discontinuing MAO inhibitors. Severe hypertension or coronary artery disease. Narrow-angle glaucoma. Urinary retention. Use in children under 12 years.
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (contraindicated). Caffeine may increase stimulant effects. Alcohol increases sedation. Grapefruit juice may affect metabolism of pseudoephedrine.
No known food interactions. Alcohol consumption is not restricted.
Triaminic-12 (acetaminophen 500 mg, pseudoephedrine 30 mg, dextromethorphan 15 mg, chlorpheniramine 4 mg): Acetaminophen is generally considered low risk in all trimesters; pseudoephedrine is associated with a possible increased risk of gastroschisis in the first trimester; dextromethorphan has limited data but no clear teratogenic signal; chlorpheniramine is considered safe in pregnancy. FDA pregnancy category varies by component: acetaminophen B, pseudoephedrine C, dextromethorphan C, chlorpheniramine B. Overall, avoid in first trimester if possible due to pseudoephedrine.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Acetaminophen is compatible with breastfeeding. Pseudoephedrine passes into breast milk (M/P ratio approximately 3.3) and may reduce milk supply; avoid if possible. Dextromethorphan has limited data but considered low risk. Chlorpheniramine is compatible but may cause drowsiness in infant. Overall, use with caution and monitor infant for sedation.
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
No specific dose adjustments recommended for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Pseudoephedrine should be avoided in women with hypertension or preeclampsia.
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
Triaminic-12 contains chlorpheniramine (first-generation antihistamine) and pseudoephedrine (decongestant). Avoid use in patients with hypertension, coronary artery disease, or glaucoma. The antihistamine component causes sedation; caution with driving or operating machinery. Onset of action is 30-60 minutes; duration up to 12 hours.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
Take with food to reduce stomach upset.,Do not crush or chew extended-release tablets.,Avoid alcohol and other CNS depressants.,May cause drowsiness; avoid driving until you know how you react.,Do not exceed recommended dose; may cause serious side effects.,Stop and consult doctor if symptoms persist after 7 days or if fever develops.,Do not use if you have high blood pressure, heart disease, or thyroid problems without medical advice.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIAMINIC-12 vs VOSOL HC, answered by our medical review team.
TRIAMINIC-12 is a Antihistamine Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Chlorpheniramine is an antihistamine that competitively antagonizes histamine H1 receptors, preventing histamine-mediated symptoms such as sneezing, rhinorrhea, and pruritus.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIAMINIC-12 and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIAMINIC-12 is: Oral: 1 tablet (75 mg of pseudoephedrine hydrochloride and 4 mg of chlorpheniramine maleate) every 12 hours, not to exceed 2 tablets in 24 hours.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIAMINIC-12 and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIAMINIC-12 is classified as Category C. Triaminic-12 (acetaminophen 500 mg, pseudoephedrine 30 mg, dextromethorphan 15 mg, chlorpheniramine 4 mg): Acetaminophen is generally considered low risk in all trimesters; pseudoe. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.